Multi-database analysis of HELQ expression in renal clear cell carcinoma and its clinical application value

doi:10.3877/cma.j.issn.2095-5820.2021.02.008

Abstract

Abstract:

Objective

To investigate the expression of HELQ and homologous reconbination pathway related genes in renal clear cell carcinoma (ccRCC) and the effect on patients' survival.

Methods

Expression of HELQ mRNA in ccRCC and normal samples were determined by websites of GEPIA and UALCAN. R2 website was used to analyze the relationship between the expression of HELQ mRNA and the grade of renal clear cell carcinoma. The relationship between HELQ mRNA expression and TNM staging was investigated by LinkedOmics and R2. We also used UALCAN, Kaplan-Meier Plotter, OncoLnc to detect the expression of HELQ mRNA on ccRCC patients' survival. Finally, we explored the expression of genes in homologous recombination pathway on ccRCC patients' survival. R2 website was used to analyze the survival effect of homologous recombination pathway related genes on patients with renal clear cell carcinoma.

Results

Compared to normal renal tissues, expression of HELQ was lower in clear cell renal cell carcinoma (P＜0.01). Expression of HELQ tended to decrease with grades (P＜0.01) and the stages of renal clear cell cell carcinoma. Besides patients with lymphatic metastasis and distant metastasis had lower HELQ mRNA expression (P＜0.01). Expression of HELQ was positively correlated with patients' survival (P＜0.01). The expression of 21 genes in homologous recombination pathway also influenced ccRCC patients' survival.

Conclusion

HELQ may have relationship with the development of renal clear cell cell carcinoma.

Key words: HELQ, Clear cell renal cell carcinoma, Prognosis, Website analysis

Xiaohui He, Fang Luo, Hailong Wang, Zhaoting Liu. Multi-database analysis of HELQ expression in renal clear cell carcinoma and its clinical application value[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2021, 09(02): 99-104.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2021.02.008

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2021/V09/I02/99

Figures/Tables 5

References 23

1	Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 317009.
2	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma[J]. Nature, 2013, 499(7456): 43-49.
3	Trivedi R, Dihazi GH, Eltoweissy M, et al. The antioxidant protein PARK7 plays an important role in cell resistance to Cisplatin-induced apoptosis in case of clear cell renal cell carcinoma[J]. Eur J Pharmacol, 2016, 78499-110.
4	Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2017, 376(4): 354-366.
5	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J]. Science, 2018, 359(6377):801-806.
6	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813.
7	Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 125-134.
8	Harmon CS, DePrimo SE, Figlin RA, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-naive patients with metastatic renal cell carcinoma[J]. Cancer Chemother Pharmacol, 2014, 73(1): 151-161.
9	Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase Ⅲ trial[J]. Lancet, 2008, 372(9637): 449-456.
10	Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med, 2007, 356(22): 2271-2281.
11	Parikh M, JrLara PN. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type[J]. Annu Rev Med, 2018, 69209-221.
12	Marini F, Kim N, Schuffert A, et al. POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308[J]. J Biol Chem, 2003, 278(34): 32014-32019.
13	Han X, Zhao L, Li X. HELQ in cancer and reproduction[J]. Neoplasma, 2016, 63(6): 825-835.
14	Adelman CA, Lolo RL, Birkbak NJ, et al. HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis[J]. Nature, 2013, 502(7471): 381-384.
15	Liu DN, Zhou YF, Peng AF, et al. HELQ reverses the malignant phenotype of osteosarcoma cells via CHK1-RAD51 signaling pathway[J]. Oncol Rep, 2017, 37(2): 1107-1113.
16	Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
17	Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses[J]. Neoplasia, 2017, 19(8): 649-658.
18	Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(1):956-963.
19	Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma[J]. R Soc Open Sci, 2018, 5(12): 181006.
20	Dagher J, Delahunt B, Rioux-Leclercq N, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading[J]. Histopathology, 2017, 71(6): 918-925.
21	Piazza A, Heyer WD. Homologous Recombination and the Formation of Complex Genomic Rearrangements[J]. Trends Cell Biol, 2019, 29(2): 135-149.
22	Mouw KW, Goldberg MS, Konstantinopoulos PA, et al. DNA Damage and Repair Biomarkers of Immunotherapy Response[J]. Cancer Discov, 2017, 7(7): 675-693.
23	O'Connor MJ. Targeting the DNA Damage Response in Cancer[J]. Mol Cell, 2015, 60(4): 547-560.

同源重组修复通路基因(来自KEGG)	P 值 (高表达vs低表达)	短生存期患者表达水平(相对于正常人)
EME1	P＜0.01	高
RAD54L	P＜0.01	高
XRCC3	P＜0.01	高
RAD51	P＜0.01	高
TOP3B	P＜0.01	高
POLD1	P＜0.01	高
BLM	P＜0.01	高
RAD52	P＜0.01	高
RAD51B	P＜0.01	高
POLD4	P＜0.01	高
MUS81	P＜0.01	高
XRCC2	P＜0.01	高
RAD54B	P＜0.01	高
SHFM1	P＜0.01	高
RAD51D	P＜0.01	高
TOP3A	P＜0.01	高
RPA4	P＜0.05	高
POLD3	P＜0.05	高
RPA1	P＜0.01	低
SYCP3	P＜0.01	低
RAD50	P＜0.01	低

同源重组修复通路基因(来自KEGG)	P 值 (高表达vs低表达)	短生存期患者表达水平(相对于正常人)
EME1	P＜0.01	高
RAD54L	P＜0.01	高
XRCC3	P＜0.01	高
RAD51	P＜0.01	高
TOP3B	P＜0.01	高
POLD1	P＜0.01	高
BLM	P＜0.01	高
RAD52	P＜0.01	高
RAD51B	P＜0.01	高
POLD4	P＜0.01	高
MUS81	P＜0.01	高
XRCC2	P＜0.01	高
RAD54B	P＜0.01	高
SHFM1	P＜0.01	高
RAD51D	P＜0.01	高
TOP3A	P＜0.01	高
RPA4	P＜0.05	高
POLD3	P＜0.05	高
RPA1	P＜0.01	低
SYCP3	P＜0.01	低
RAD50	P＜0.01	低

[1]	Kang Ying, Canying Yang, Fengzhen Liu, Lili Chen, Yanna Liu. Prognostic value of left ventricular myocardial strain in asymptomatic patients with severe aortic stenosis [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 581-587.
[2]	Yuezhou Li, Kongxi Zhang, Xiaohong Li, Zhonghua Shang. Prognostic significance of PUM in gastric carcinoma based on bioinformatics analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 426-432.
[3]	Qian Yang, Cuifang Li, Wanqiu Zhang. Analysis of short-term and long-term prognosis and influencing factors of primary liver cancer with spontaneous ruptured hemorrhage after emergency TACE surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 33-36.
[4]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[5]	Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.
[6]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[7]	Xin Lu, Jiayi Xu, Yang Liu, Qin Yang, Wenwen Ju, Yinglong Xu. Comparison of the effects of early LC and PTCD continuous LC on liver function and prognosis of patients with acute cholecystitis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 648-650.
[8]	Bing Pan, Shaocheng Lyu, Xin Zhao, Lixin Li, Ren Lang, Qiang He. Effect of number of dissected lymph nodes on efficacy of pancreaticoduodenectomy for distal cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 608-612.
[9]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[10]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[11]	Weizhi Zhang, Lianxin Liu. Expression and significance of IPO7 in hepatocellular carcinoma based on bioinformatics analysis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 694-701.
[12]	Wentao Ye, Zhongjun Wu, Rui Liao. Relationship between ALOX15 expression in adjacent tissues and prognosis of hepatocellular carcinoma patients after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 708-712.
[13]	Yongsheng Li, Jiahe Sun, Shuwei Guo, Yikang Lu, Hongzhou Liu. Short-term postoperative complications and their influencing factors in elderly patients with colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 962-967.
[14]	Jun Wang, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Libin Suo, Jun Chen, chengli Miao, Chenghua Luo. Retrospective analysis of anesthesia management of massive transfusion patients undergoing retroperitoneal tumor resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 844-849.
[15]	Libin Suo, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Jun Wang, Jun Chen, Chengli Miao, Chenghua Luo. Key points of anesthesia management and prognostic factors in patients undergoing primary retroperitoneal paraganglioma resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 771-776.

Please choose a citation manager

Content to export